Danny Houtsma

1.0k total citations
19 papers, 98 citations indexed

About

Danny Houtsma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Danny Houtsma has authored 19 papers receiving a total of 98 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Danny Houtsma's work include Advanced Breast Cancer Therapies (4 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). Danny Houtsma is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). Danny Houtsma collaborates with scholars based in Netherlands, United States and Belgium. Danny Houtsma's co-authors include Henk‐Jan Guchelaar, Hans Gelderblom, Frederiek van den Bos, Loes E. Visser, JJ Swen, Vincent O. Dezentjé, Luc Dirix, Cor D. de Kroon, Pepijn Brocken and Esteban T.D. Souwer and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Danny Houtsma

16 papers receiving 98 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danny Houtsma Netherlands 6 42 38 22 22 15 19 98
Oana Cojocarasu France 6 94 2.2× 45 1.2× 25 1.1× 12 0.5× 5 0.3× 15 135
María R. Alonso Spain 5 75 1.8× 17 0.4× 46 2.1× 13 0.6× 9 0.6× 5 138
Romain Geiss France 6 54 1.3× 33 0.9× 24 1.1× 50 2.3× 43 2.9× 19 151
Cheryl J. Smith United States 8 74 1.8× 34 0.9× 47 2.1× 41 1.9× 10 0.7× 10 169
Roel van Kampen Netherlands 5 75 1.8× 12 0.3× 34 1.5× 25 1.1× 22 1.5× 8 167
Kasper Madsen Denmark 8 123 2.9× 29 0.8× 68 3.1× 23 1.0× 24 1.6× 32 255
Leonardo Provenzano Italy 6 38 0.9× 17 0.4× 27 1.2× 19 0.9× 38 2.5× 21 114
Belén Herráez Spain 6 46 1.1× 19 0.5× 68 3.1× 63 2.9× 8 0.5× 8 133
Gustavo Vasconcelos Alves Brazil 7 40 1.0× 47 1.2× 30 1.4× 16 0.7× 6 0.4× 20 128
Javier Lanillos Spain 6 28 0.7× 47 1.2× 56 2.5× 35 1.6× 9 0.6× 10 97

Countries citing papers authored by Danny Houtsma

Since Specialization
Citations

This map shows the geographic impact of Danny Houtsma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny Houtsma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny Houtsma more than expected).

Fields of papers citing papers by Danny Houtsma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danny Houtsma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny Houtsma. The network helps show where Danny Houtsma may publish in the future.

Co-authorship network of co-authors of Danny Houtsma

This figure shows the co-authorship network connecting the top 25 collaborators of Danny Houtsma. A scholar is included among the top collaborators of Danny Houtsma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danny Houtsma. Danny Houtsma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Konings, Inge R., Vincent van der Noort, E. van den Pol, et al.. (2025). Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial. European Journal of Cancer. 231. 116051–116051. 1 indexed citations
2.
Stevens, Michiel, John W.M. Martens, Jaco Kraan, et al.. (2025). PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients. Cancer Research Communications. 5(8). 1359–1371.
3.
Cohen, Danielle, Joan B. Heijns, Caroline M.P.W. Mandigers, et al.. (2025). Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01). Clinical Cancer Research. 31(15). 3175–3181.
4.
Bos, Frederiek van den, Marije Slingerland, Gerrit‐Jan Liefers, et al.. (2024). DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients. BMJ Open. 14(8). e089882–e089882.
5.
Kent, Stephen B. H., Inge R. Konings, Vincent van der Noort, et al.. (2024). 352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03). Annals of Oncology. 35. S364–S364. 1 indexed citations
6.
Mooijaart, Simon P., Annelie Vulink, Danny Houtsma, et al.. (2024). Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer. Breast Cancer Research and Treatment. 206(2). 337–346. 3 indexed citations
7.
Lugtenberg, Rieneke T., Stefanie de Groot, Danny Houtsma, et al.. (2023). Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer. Cancers. 15(6). 1691–1691. 4 indexed citations
8.
9.
Wilms, Erik B., Pepijn Brocken, Henk Codrington, et al.. (2022). Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study. Journal of Geriatric Oncology. 13(7). 997–1002. 6 indexed citations
10.
Lugtenberg, Rieneke T., Corina van den Hurk, Carolien H. Smorenburg, et al.. (2022). Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia — a randomized controlled trial. Supportive Care in Cancer. 30(8). 6641–6648. 3 indexed citations
11.
Groenwold, Rolf H. H., Tom van der Hulle, Loes E. Visser, et al.. (2022). Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. Frontiers in Pharmacology. 13. 803935–803935. 11 indexed citations
12.
Viddeleer, Alain R., Johannes W. Trum, Frédéric Amant, et al.. (2021). Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer. Gynecologic Oncology. 162(2). 360–367. 15 indexed citations
13.
Houtsma, Danny, Stefanie de Groot, Renée Baak-Pablo, et al.. (2021). The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. Scientific Reports. 11(1). 3249–3249. 3 indexed citations
14.
Zande, Kim van der, Vincent van der Noort, Paul Hamberg, et al.. (2021). First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(15_suppl). 5059–5059. 3 indexed citations
15.
Gisbertz, Ingrid, Willem Moolenaar, Yvonne Hendriks, et al.. (2018). Variable workup calls for guideline development for type 2A hereditary haemochromatosis.. PubMed. 76(8). 365–373. 2 indexed citations
16.
Kanefendt, Friederike, JJ Swen, F. Sörgel, et al.. (2017). Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer. CPT Pharmacometrics & Systems Pharmacology. 6(9). 604–613. 19 indexed citations
17.
Houtsma, Danny, D.B.Y. Fontein, Tahar van der Straaten, et al.. (2013). Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial.. Journal of Clinical Oncology. 31(15_suppl). e22152–e22152. 1 indexed citations
18.
Fontein, D.B.Y., Danny Houtsma, E.T.M. Hille, et al.. (2012). Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. Annals of Oncology. 23(12). 3091–3097. 11 indexed citations
19.
Houtsma, Danny, Henk‐Jan Guchelaar, & Hans Gelderblom. (2009). Pharmacogenetics in Oncology: A Promising Field. Current Pharmaceutical Design. 16(2). 155–163. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oana Cojocarasu Breakdown of academic impact, for papers by María R. Alonso Breakdown of academic impact, for papers by Romain Geiss Breakdown of academic impact, for papers by Cheryl J. Smith Breakdown of academic impact, for papers by Roel van Kampen Breakdown of academic impact, for papers by Kasper Madsen Breakdown of academic impact, for papers by Leonardo Provenzano Breakdown of academic impact, for papers by Belén Herráez Breakdown of academic impact, for papers by Gustavo Vasconcelos Alves Breakdown of academic impact, for papers by Javier Lanillos
Rankless by CCL
2026